Sign in

Private company

Bellerophon Therapeutics (United States)

American pharmaceutical preparations company based in Warren, founded in 20091

In its 2023 annual report the company says: “We are a clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Our focus is the continued development of our nitric oxide therapy for patients with or at risk of pulmonary hypertension, or PH, using our proprietary pulsatile nitric oxide delivery platform, INOpulse.”69

Last updated Oct 21, 2026.

Overview

2009Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWarren1
  • Websitewww.bellerophon.com
  • Incorporated inDE3
  • Business address184 Liberty Corner Road, Suite 302, Warren, Nj 070593
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$22.4M in 2022−6% since 2016
-$30.0M-$20.0M-$10.0M02016: -$23.8M-$23.8M20162017: -$24.6M-$24.6M2017+4%2018: -$27.9M-$27.9M2018+13%2019: -$17.5M-$17.5M2019−37%2020: -$26.3M-$26.3M2020+50%2021: -$20.2M-$20.2M2021−23%2022: -$22.4M-$22.4M2022+11%
Net income45678-$19.8M in 2022−17% since 2016
-$60.0M-$40.0M-$20.0M0$20.0M2016: -$23.8M-$23.8M20162017: -$54.8M-$54.8M2017+130%2018: $2.8M$2.8M20182019: -$13.3M-$13.3M20192020: -$24.7M-$24.7M2020+86%2021: -$17.8M-$17.8M2021−28%2022: -$19.8M-$19.8M2022+12%
Fiscal year20162017201820192020202120222023
Operating expenses$20.2M8$22.4M8
Operating income-$23.8M4-$24.6M5-$27.9M6-$17.5M7-$26.3M8-$20.2M8-$22.4M8
Income before tax-$19.6M8-$22.2M8
Income tax-$438.0K4$05-$5.4M6-$1.8M7-$2.1M8-$1.8M8-$2.4M8
Net income-$23.8M4-$54.8M5$2.8M6-$13.3M7-$24.7M8-$17.8M8-$19.8M8
Earnings per share-$1.584-$21.115$0.736-$2.957-$3.178-$1.878-$2.088
Earnings per share (diluted)-$1.584-$21.115-$5.076-$2.957-$3.178-$1.878-$2.088
Shares (weighted, basic)9.5M shares89.6M shares8
Shares (weighted, diluted)9.5M shares89.6M shares8

Compare Bellerophon Therapeutics (United States) with another company

Corporate structure

Bellerophon Therapeutics (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Bellerophon Therapeutics (United States)

  • Michael Aaron Nelson Filed SCHEDULE 13G on Bellerophon Therapeutics (United States), latest Mar 1, 2024 (2 filings since Jan 26, 2024)
  • PERCEPTIVE ADVISORS LLC Filed SC 13G/A on Bellerophon Therapeutics (United States), latest Feb 14, 2024 (2 filings since Mar 14, 2023)
  • TANG CAPITAL PARTNERS LP Filed SC 13G/A on Bellerophon Therapeutics (United States), latest Feb 14, 2024 (2 filings since Mar 17, 2023)
  • Lepercq De Neuflize Asset Management LLC Filed SC 13G on Bellerophon Therapeutics (United States), latest Jan 26, 2024
  • PCM Ai Opportunities Fund Filed SC 13D/A on Bellerophon Therapeutics (United States), latest Oct 18, 2023 (4 filings since May 22, 2023)
  • Janus Henderson Group Ltd. Filed SC 13G/A on Bellerophon Therapeutics (United States), latest Jun 9, 2023 (3 filings since May 25, 2023)
  • New Mountain Investments II, LLC Filed SC 13G/A on Bellerophon Therapeutics (United States), latest Feb 14, 2022
  • Bellerophon Therapeutics (United States) Warren

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Bellerophon Therapeutics (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.5M8 Dec 31, 2022$2.5M8 Dec 31, 20210%
Accumulated depreciation$2.5M8 Dec 31, 2022$2.5M8 Dec 31, 2021+2.6%
Property and equipment, net$2.0K8 Dec 31, 2022$67.0K8 Dec 31, 2021−97.0%
Operating-lease assets (leased space)$184.0K8 Dec 31, 2022$863.0K8 Dec 31, 2021−78.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.9M8 Dec 31, 2022$24.7M8 Dec 31, 2021−72.0%

Leadership

Who has led Bellerophon Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jonathan M. Peacock2015–2016
  2. Fabian Tenenbaum2016–2019
  3. Peter Fernandes2023

President

  1. Jonathan M. Peacock2015–2016

Chief financial officer

  1. Fabian Tenenbaum2016
  2. Assaf Korner2018–2019

Chief operating officer

  1. Amit Agrawal2015
2010201520202025
Board members and other officers (25)

Former names

  • Bellerophon Therapeutics LLCFeb 21, 2014 to Feb 13, 20153

Timeline

  1. Mar 4, 20248-K Executive or director change; Shareholder vote43
  2. Jan 30, 20248-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights44
  3. Jan 22, 20248-K Shareholder vote; Other events45
  4. Jan 10, 20248-K Shareholder vote; Other events46
  5. Dec 12, 20238-K Shareholder vote; Other events47
  6. Nov 21, 20238-K Executive or director change48
  7. Oct 13, 20238-K Listing notice or transfer; Other events49
  8. Oct 13, 20238-K Executive or director change50
  9. Aug 7, 20238-K Executive or director change51
  10. Jul 24, 20238-K Listing notice or transfer52
  11. Jul 20, 20238-K Executive or director change53
  12. Jul 14, 20238-K Executive or director change54
  13. Feb 14, 2023New chief executive Peter Fernandes becomes CEO13
  14. Nov 15, 2016New chief executive Fabian Tenenbaum becomes CEO14
  15. Feb 13, 2015New chief executive Jonathan M. Peacock becomes CEO15
  16. 2009Founded Founded1

Calendar

When it reported results

  1. May 15, 2023Reported quarterly or annual results55
  2. Mar 31, 2023Reported quarterly or annual results56
  3. Nov 14, 2022Reported quarterly or annual results57
  4. Aug 15, 2022Reported quarterly or annual results58
  5. May 11, 2022Reported quarterly or annual results59
  6. Mar 31, 2022Reported quarterly or annual results60
  7. Nov 15, 2021Reported quarterly or annual results61

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

131 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 40 major events, 37 insider forms, 15 large holders, 30 other. The latest 20:

  1. Mar 6, 202415-12G EDGAR
  2. Mar 4, 20248-K EDGAR
  3. Mar 1, 2024SCHEDULE 13G EDGAR
  4. Feb 14, 2024SC 13G/A AMENDMENT NO. 1 EDGAR
  5. Feb 14, 2024SC 13G/A EDGAR
  6. Feb 12, 2024DEFA14A EDGAR
  7. Feb 12, 2024DEFA14A EDGAR
  8. Jan 30, 20248-K EDGAR
  9. Jan 26, 2024SCHEDULE 13G EDGAR
  10. Jan 26, 2024SC 13G EDGAR
  11. Jan 22, 20248-K EDGAR
  12. Jan 10, 20248-K EDGAR
  13. Jan 3, 2024DEFA14A EDGAR
  14. Dec 12, 20238-K EDGAR
  15. Nov 21, 20238-K EDGAR
  16. Nov 14, 202310-Q EDGAR
  17. Nov 6, 2023DEF 14A EDGAR
  18. Oct 27, 2023PRE 14A EDGAR
  19. Oct 18, 2023SC 13D/A EDGAR
  20. Oct 17, 2023SC 13D/A EDGAR

The 131 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 0 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 13, 2023Puissance Life Science Opportunities Fund VI10% ownerSale1,076,841$0.10$107.7KForm 4
Jun 7, 2023Puissance Capital Management LP10% ownerSale134,421$0.83$111.6KForm 4
May 18, 2023Puissance Capital Management LP10% ownerSale560,000$9.46$5.3MForm 4
May 18, 2023Kim BobaeVP Reg. Affairs & QualitySale9,455$10.00$94.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Bellerophon Therapeutics (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBellerophon Therapeutics, Inc.2
  • CIK0001600132
  • Employer ID (EIN)47-31161752
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address184 Liberty Corner Road, Suite 302, Warren, NJ 070592
  • Phone908-574-47702
  • Shares outstanding12,232,648 as of Nov 10, 202311
  • Public float$8.8M as of Jun 30, 20228
  • On EDGAR sinceFeb 21, 20142
  • Filings643 in all: 4 (242), 8-K (157), 3 (36), 10-Q (27), SC 13G/A (20), CORRESP (14), 424B5 (12), SC 13G (12)2
    All 44 form types

    DEFA14A (11), DEF 14A (10), UPLOAD (10), 10-K (9), SC 13D/A (9), S-8 (8), S-8 POS (8), EFFECT (7), S-3 (5), D (4), S-1/A (4), 8-K/A (3), PRE 14A (3), 10-K/A (2), 144 (2), 424B2 (2), CT ORDER (2), DRS/A (2), DRSLTR (2), S-1 (2), SC 13D (2), SCHEDULE 13G (2), 15-12G (1), 25-NSE (1), 424B3 (1), 424B4 (1), 5 (1), 8-A12B (1), ARS (1), CERTNAS (1), DRS (1), NT 10-K (1), POS EX (1), RW (1), S-1MEF (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2023
    Quarterly report (10-Q) Nov 14, 2023
    Proxy statement (DEF 14A) Nov 6, 2023
    Latest 8-K (8-K) Mar 4, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69